No Picture
News

Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting

SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab … […]

No Picture
News

Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting

SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-sma… […]

No Picture
News

Synthorx to Present Preclinical Data for THOR-707, a “Not-Alpha” IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2018

SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Synthorx, Inc., a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune disorders, today announced … […]

No Picture
News

Free Flying with Falcons

Below your feet, hundreds of brightly colored umbrellas paint the picturesque beach. Above, a shimmering parachute suspends you as you glide soundlessly through the air. Then, seemingly out of nowhere, a falcon … […]

No Picture
News

Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Announced Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol (LDL-C)- Presented Positive Results from Phase 2 … […]